BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Merck Presents Longer-Term Phase 3 Data Showing Pimicotinib Achieves 76.2% Objective Response Rate in TGCT

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...

October 20, 2025 | News

PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...

October 17, 2025 | News

Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary

Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...

October 16, 2025 | News

SK Bioscience Files Clinical Trial Application in Australia for GBP511 Universal Coronavirus Vaccine

Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses Phase 1/2 study to enroll ~500 healthy adults, with topline results e...

October 16, 2025 | News

Ascletis’ Denifanstat (ASC40) Achieves Phase III Success in Moderate-to-Severe Acne Vulgaris

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulga...

October 15, 2025 | News

Clover Biopharmaceuticals Reports Promising Phase I Results for RSV+hMPV±PIV3 Combination Vaccines

Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously...

October 15, 2025 | News

Ascletis Selects ASC35 as Once-Monthly, Dual GLP-1/GIP Peptide Agonist Candidate for Obesity Treatment

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, whic...

October 14, 2025 | News

GC Biopharma Secures Global CMO Rights for Curevo’s Recombinant Shingles Vaccine

GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced that it has signed an agreement with Curevo Vaccine to secure contract manufa...

October 14, 2025 | News

Anthony Elgamal: Redefining First-Line Treatment in EGFR-Mutated Lung Cancer

BioPharma APAC speaks with Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific, on th...

October 13, 2025 | Expert Insight

Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial

The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...

October 13, 2025 | News

Renalys Pharma Completes Primary Endpoint Data Collection in Phase III Sparsentan Trial for IgA Nephropathy

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced that it has completed data collection for the primary endpoint in the Phase I...

October 13, 2025 | News

Berlin Heals Completes Enrollment in First-in-Human Study of Less Invasive Heart Failure Therapy

Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a major Cardiology Congress ...

October 13, 2025 | News

Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy

Efficacy signals were observed in an interim analysis of a Phase 2 clinical trial for ONO-2808, a S1P5 receptor agonist Phase 2 clinical trial was con...

October 13, 2025 | News

C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical

C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...

October 13, 2025 | News

Stay Connected